NZ565878A

NZ565878A - 2,5-substituted 3-undecyl-1,4-benzoquinones

Info

Publication number: NZ565878A
Application number: NZ565878A
Authority: NZ
Inventors: Shakti Upadhyay; Raman Yadav; Vijay Gangan; Yogesh Kanekar
Original assignee: Reliance Life Sciences Pvt Ltd
Priority date: 2005-07-21
Filing date: 2005-09-19
Publication date: 2010-04-30
Also published as: CA2614585A1; RU2420513C2; IL188894A0; AU2005334672A1; WO2007010546A1; CN101228108A; KR20080030044A; EP1937622A1; ZA200800567B; KR100928954B1; RU2008106628A; BRPI0520515A2; JP2009505953A

Abstract

Disclosed is the use of 2,5-dihydroxy-3-undecyl-p-benzoquinine or an analog thereof having the formula (I), wherein the substituents are as defined in the specification, optical isomers thereof, polymorphs thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of said compounds, said isomers of said polymorphs, salts, solvates and hydrates thereof, in the manufacture of a medicament for use in a method for treatment, amelioration or prevention of a disease or condition mediated by a lipase gene family enzyme, including obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, diabetes, atherosclerosis, other cardiovascular diseases, metabolic syndromes and metabolic disorders. Cosmetic methods for the skin and hair are also provided. Certain novel compounds of formula (I) are also disclosed.

Description

<div class="application article clearfix" id="description"> New Zealand Paient Spedficaiion for Paient Number 565878 565878 WO 2007/010546 PCT/IN2005/000318 TITLE: "COMPOUNDS FOR TREATMENT OF LIPASE-MEDIATED DISEASES" Technical Field of the Invention The present invention relates to novel heterocyclic compounds of benzoquinones that affect the activity of enzymes of lipase gene family. The present invention relates to pharmaceutical compositions that contain the benzoquinone derived compounds, process for preparing the same and their pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates thereof having a selective activity on diseases and conditions mediated by genes of lipase family. BACKGROUND OF THE INVENTION In many developed and developing countries, the trend towards adoption of a diet containing high fat content and low fiber concentrations continuous to be on the rise, accompanied by a labor-unintensive sedentary lifestyle. Such excessive intake of fat, accompanied by reduced conversion of fat into energy because of sedentary lifestyles can lead to accumulation of fat in the body at various levels including body fluids, cells and tissues. Consequently there is a steady rise in a population at a heightened risk of metabolic disorders such as overweight or obesity, which progresses to associated disorders like diabetes, cardiovascular disorders, metabolic syndrome, and hypertension. In general the first line of treatment for individuals suffering from such metabolic disorders, in particular overweight or obesity, involves adoption of a diet low in fat and regular exercise. Compliance with such regimen however can be poor and, as the disease progresses, treatment with therapeutic drugs becomes necessary. Accordingly, studies have been made towards developing drugs that are safe and effective for prevention and treatment of clinical manifestations that are caused as a consequence of accumulation of fat in body fluids, cells and tissues. Thus, there is a continuing necessity for decreasing the absorption and accumulation of fat in the body in some manner. 1 565878 WO 2007/010546 PCT/IN2005/000318 One approach to prevent or reduce fat accumulation is by reducing or inhibiting agents that aid in digestion and absorption of fat at various levels in the body. Enzymes belonging to the lipase gene family are of the central importance in lipid metabolism, absorption and transportation. Hepatic lipase and lipoprotein lipase are multifunctional proteins which mediate the binding, uptake, catabolism, and remodeling of lipoproteins and phospholipids. Lipoprotein lipase and hepatic lipase function while bound to the luminal surface of endothelial cells in peripheral tissues and the liver respectively. -Both enzymes participate in reverse cholesterol transport, which is the movement of cholesterol from peripheral tissues to the liver either for excretion from the body or for recycling. Genetic defects in both hepatic lipase and lipoprotein lipase are known to be the cause of familial disorders of lipoprotein metabolism. Defects in the metabolism of lipoproteins result in serious metabolic disorders, including hypercholesterolemia, hyperlipidemia, and atherosclerosis. The lipase gene family enzymes are involved in a wide array of metabolic pathways, ranging from lipid digestion, absorption, fatty acid uptake, lipoprotein transportation and also in inflammation (Wong Howard et al., 2002, The lipase gene family, Journal of Lipid Research, Vol. 43: 993-999). Pancreatic lipase is one of the key enzymes in lipid metabolism. It is synthesized by pancreatic acinar cells where it is secreted into the intestinal lumen and aids in the intestinal absorption of long chain triglyceride fatty acids (Verger, R. 1984, Pancreatic Lipases In Lipases. B. Borgstrom and H.L. Brockman, editors. Elsevier, New York. 83-150; Lowe, M. E. 1997, Molecular mechanisms of rat and human pancreatic triglyceride lipases. J. Nutr. 127: 549-557). The action of the triacylglycerol lipases is believed to be antiatherogenic because these enzymes lower serum triacylglycerol levels and promotes HDL formation. (Olivecrona, G., and Olivecrona, T. (1995) Curr. Opin. Lipid. 6:291-305). Lipoprotein lipase is the major enzyme responsible for the distribution and utilization of triglycerides in the body. Lipoprotein lipase hydrolyzes triglycerides in both chylomicrons and VLDL. Hepatic lipase hydrolyzes triglycerides in IDL and HDL, and is responsible for lipoprotein 2 WO 2007/010546 PCT/IN2005/000318 remodeling. Hepatic lipase also functions as a phospholipase, and hydrolyzes phospholipids in HDL. Lipase members function in the metabolism of circulating lipoproteins. Hepatic lipase plays a role in the uptake of HDL cholesterol (Olivecrona, T., et al. 1993, Lipoprotein lipase and hepatic lipase. Curr. Opin. Lipidol. 4: 187-196). It is synthesized exclusively in the liver, where it is predominantly found (Hixenbaugh, E. A, et al., 1989, Hepatic lipase in the rat ovary. J. Biol. Chem. 264: 4222-4230). A third member of the lipase gene family, lipoprotein lipase (LPL), is distributed in a variety of tissues, with the highest concentrations occurring in adipose tissue and muscle. This lipase is bound to capillary endothelium, where it functions to supply the underlying tissue with fatty acids derived from the triglyceride-rich core of circulating chylomicrons and VLDL (Olivecrona, T., and G. Bengtsson-Olivecrona. 1993. Lipoprotein lipase and hepatic lipase. Curr, Opin. Lipidol. 4: 187-196). In the process, LPL transforms these lipoproteins into remnant and HDL particles. Accumulating evidence suggest that LPL produced by macrophages in the vascular wall may facilitate the development of atherosclerosis by promoting lipid accumulation within the lesion. LPL has been shown to be involved in the pathogenesis of atherosclerosis (Mead JR, et al. 1999, "Lipoprotein Lipase, a key role in atherosclerosis?" FEBS Lett., Nov 26, 462(1-2): 1-6). Several groups have also proposed that both LPL and hepatic lipase besides their traditional role as lipolytic enzyme also appear to serve as ligands in the metabolism of plasma lipoproteins (Nykjaer, A., et al., 1993, The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and beta-migrating very low density lipoprotein associated with the lipase. J. Biol. Chem. 268: 15048-15055; Krapp, A., S. et al., 1996. Hepatic lipase mediates the uptake of chylomicrons and VLDL into cells via the LDL receptor-related protein (LRP). J. Lipid Res. 37: 926-936). Transgenic animals expressing human lipoprotein lipase or hepatic lipase have decreased levels of plasma triglycerides and an increased level of high density lipoprotein (HDL) (Shimada, M., et al (1993) J. Biol. Chem. 268:17924-17929; Liu, M.-S., et al. (1994) J. Biol. Chem. 269:11417-11424). 565878 WO 2007/010546 PCT/IN2005/000318 A more recently discovered member of the lipase gene family is endothelial lipase. The function of this lipase is though uncertain at this time, it is believed to have a role in HDL metabolism (Jaye, M., et al., 1999, A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21: 424—428). With the increasingly recognized potential of lipases in fat metabolism pathway, the drugs that inhibit or reduce the activity of lipases at various levels in the body form the front line of therapy for the treatment of diseases mediated by accumulation of fat at elevated levels. A lipase inhibitor that is marketed as anti-obesity drug include Orlistat (XENICAL®) is described in U.S. Patent No. 4598089. European Patent Application No. EP129748, relates to Orlistat and related compounds and their use in inhibiting pancreatic lipase and treating hyperlipidemia and obesity. Orlistat inhibits only intestinal lipases such as gastric, pancreatic and carboxylester lipases, particularly pancreatic lipase, in the gut lumen and blocks the digestion of dietary fat by preventing lipase from interacting with its lipid target. It however does not appear to have an effect on lipases other than the intestinal lipases, such as hepatic lipase or endothelial lipase, which are also recognized as having roles in catalyzing the hydrolysis of lipids. (Drent ML, van der Veen EA. Lipase inhibition: A novel concept in the treatment of obesity. Int J. Obes. Relat. Metab. Disord. 1993; 17:241-244.) Orlistat also tends to produce a high incidence of unpleasant (relatively harmless) side effects such as diarrhea. Compounds that inhibit hepatic lipase and/or endothelial lipase activity have been disclosed in PCT Application No. W02004094393 for the treatment of hepatic and/or endothelial lipase mediated diseases. The compounds are primarily directed towards increasing HDL levels by inhibiting the activity of hepatic and/or endothelial lipase, and are not intended to target intestinal or other lipases. Therefore, it is desirable to develop new compounds that are useful in reducing or inhibiting metabolism, absorption, and accumulation of fat at various levels including fluids, cells, and tissues in the body by inhibiting or reducing the activity of all members of lipase gene family of interest and not just a particular type of lipase. 4 565878 RECEIVED at IPONZ on 26 March 2010 A plant benzoquinone embelin (2,5-dihydroxy-3-uiidecyi-l,4-beii20quuione) obtained from the dried fruit of Embelia ribes and known as an antifertility agent has also been reported to elevate activities of the lipogenic enzymes, malate dehydrogenase, glucose-6-phosphate dehydrogenase and hydroxymethylglutaryl-CoA reductase while essentially not affecting lipolytic enzyme activities. (Gupta S. et al., Fitoterapia 60(4):331-338 (1989).) Embelin is also used as a teniacide, as having antitumor, anti-inflammatory and analgesic properties (Chitra et al. Chemotherapy 40:109 (1994)) and as a cell-permeable, non-peptide inhibitor of X-linked inhibitor of apoptosis (XIAP). (Nikolovska-Coleska et al. J. Med. Chem. 47:2430 (2004)). It is an object of the present invention to go some way towards providing this desideratum and/or to provide the public with a useful choice. SUMMARY OF THE INVENTION In a first aspect the invention provides a use of a compound selected from 2,5-dihydroxy-3-undecyl-p-benzoquinine, the compounds of any one of formulae (I), (II) and (III), optical isomers thereof, polymorphs thereof, and pharmaceutical^ acceptable esters, ethers, carbamates, oximes of said compounds, said isomers or said polymorphs, all solvates and hydrates thereof and all salts thereof, in the manufacture of a medicament for use in a method for treatment, amelioration or prevention of a disease or condition mediated by a lipase gene family enzyme comprising inhibiting or reducing activity of an enzyme belonging to lipase gene family to an extent that treats, ameliorates or prevents the disease or condition 5 565878 RECEIVED at IPONZ on 16 December 2009 O (I) o wherein Ri and R2 are each independently selected from the group consisting of hydrogen, C3-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 arylamine, C(0)Ci-C6 alkyl, 0-C(0)Ci-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, C(0)aryl and 0-C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, Ci-Cg alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that Ri and R2 are not phenyl; wherein R/ and R/ are each independently selected from the group consisting of C3-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-Ce cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 arylamine, C(0)Ci-Ce alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that R/ and R2 are not phenyl; 0 5a RECEIVED at IPONZ on 26 March 2010 565878 (III) 10 o wherein Ri/y and R2" are each independently selected from the group consisting of hydrogen, C1-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-Ci3 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C13 alkylamine, C1-C13 arylamine, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C(0)Ci-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups. In a second aspect the invention provides a compound selected from the compounds of any one of formulae (la), (Ila) and (Ilia), optical isomers thereof, polymorphs thereof, and pharmaceutical^ acceptable esters, ethers, carbamates, oximes of said compounds, said isomers or said polymorphs, all solvates and hydrates thereof and all salts thereof: 5b 565878 RECEIVED at IPONZ on 26 March 2010 O (la) O wherein Ri and R2 are each independently selected from the group consisting of (a) C1-C13 arylamine and 0-C(0)aryl groups which carry 1 to 6 substituents, and (b) C3-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C3-C13 alkylamine, C(0)Ci-C6 alkyl, 0-C(0)C2-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl groups which optionally carry 1 to 6 substituents, wherein said substituents are independently selected from halo, nitro, amino, cyano, isocyano, thio, C2-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that Ri and R2 are not phenyl; wherein R/ and R27 are each independently selected from the group consisting of (a) a C(0)aryl group which carries 1 to 6 substituents, and (b) C3-C13 alkyl, C|-C2o haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 arylamine, C(0)C2-C6 alkyl, heterocycloalkyl, aryl, and alkylaryl groups which optionally (Ha) 0 0 5c 565878 RECEIVED at IPONZ on 26 March 2010 carry 1 to 6 substituents wherein said substituents are independently selected from halo, nitro, amino, cyano, isocyano, thio, C]-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that R/ and R2y are not phenyl; wherein R\" and R2;y are each independently selected from the group consisting of (a) an aryl group which carries 1 to 6 substituents, and (b) hydrogen, C2-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C13 alkylamine, C1-C13 arylamine, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C(0)Ci-C6 alkyl, heterocycloalkyl, alkylaryl, and C(0)aryl groups which optionally carry 1 to 6 substituents, wherein said substituents are independently selected from halo, nitro, amino, cyano, isocyano, thio, Ci-Ce alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups. In a third aspect the invention provides a pharmaceutical composition comprising a compound of the invention, and a pharmaceutically acceptable inert adjuvant, diluent or carrier. In a fourth aspect the invention provides a pharmaceutical composition comprising a compound of the invention, and at least one additional pharmaceutically active agent. 0 O (Ilia) 5d 565878 RECEIVED at IPONZ on 16 December 2009 In a fifth aspect the invention provides a composition for skin or hair care or cosmetic preparation comprising a compound of the invention, and an inert adjuvant, diluent or carrier. Also described are compounds of Formula (I): Ri and Ra are each independently selected from the group consisting of hydrogen, C3-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, Ci-Cs alkylcycloalkyl, C1-C5 alkylcycloalkenyl, Ci-Cu alkylamine, C1-C13 arylamine, C(0)Ci-C6 alkyl, 0-C(0)Ci-Cfi alkyl, heterocycloalkyl, aiyl, alkylaryl, C(0)axyl and 0-C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aiyl, alkoxy, and aryloxy groups. However in accordance with the present invention Ri and R2 are not methyl, methoxy, ethyl, ethoxy, phenyl, and hydroxy. The present invention also relates to the compounds of formula (D and derivatives thereof including but not limited to polymorphs, isomers and prodrugs thereof, geometric or O O wherein: 5e 565878 RECEIVED at IPONZ on 16 December 2009 WO 2007/010546 PCT/IN2005/000318 optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates of such compounds, all solvates and hydrates thereof and all salts thereof. Also described is a use of compounds of formula (I) in reducing or inhibiting metabolism, absorption, and accumulation of fat at various levels including fluid, cellular, and tissue levels in body by inhibiting or reducing the activity of enzymes belonging to lipase gene family. Also described are compounds of formula (II): Ri and Ra are each independently selected from the group consisting of C3-C13 alkyl, Cr C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C5 cycloalkyl, C4-Q cycloalkenyl, Ci-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, Cr C13 arylamine, C(0)Cj-C6 alkyl, heterocycloalkyl, aiyl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aiyl, alkoxy, and aiyloxy groups. However in accordance with the present invention Rj and R3 are not methyl, ethyl, and phenyl. Also described are compounds of formula (II) and derivatives thereof including but not limited to polymorphs, isomers and prodrugs thereof, geometric or optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates of such compounds, all solvates and hydrates thereof and all salts thereof. Also described is the use of compounds of formula (II) in reducing or inhibiting metabolism, absoiption, and accumulation of fat at various levels including fluid, cellular, and tissue levels in body by inhibiting or reducing the activity of enzymes belonging to lipase gene family. O O wherein: 6 565878 WO 2007/010546 Also described are compounds of formula (III): O V o O wherein: RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 Ri and R2 are each, independently selected from the group consisting of hydrogen, Ci-Cn alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-Cs cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C13 alkylamine, C1-C13 arylamine, C1-C5 alkylcycloalkyl, Ci-Cj alkylcycloalkenyl, C(0)Ci-Q alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, Ci-Ce alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups. Also described are compounds of formula (III) and derivatives thereof including but not limited to polymorphs, isomers and prodrugs thereof, geometric or optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates of such compounds, all solvates and hydrates thereof and all salts thereof. Also described is a use of compounds of formula (III) in reducing or inhibiting metabolism, absoiption, and accumulation of fat at various levels including fluid, cellular, and tissue levels in body by inhibiting or reducing the activity of enzymes belonging to lipase gene family. Also described is the process for preparation of compounds of formulas (I), (II) and (ID) and derivatives thereof. The present invention provides a pharmaceutical compositions comprising any of the compounds of this invention including their polymorph, prodrug, isomer or pharmaceutically acceptable ester, ethers, carbamate, and oximes useful in reducing or inhibiting activity of enzymes of lipase gene family participating in metabolism, 7 WO 2007/010546 RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 absoiption, and accumulation of lipids in body at various levels including body fluid, cellular and tissue level for treatment, amelioration or prevention of diseases mediated by lipase gene family enzyme including but not limited to overweight or obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, hyperglycemia, atherosclerosis, metabolic syndromes, other cardiovascular diseases, and other metabolic disorders. Also described is the use of compounds of formulas (I), (II) and (IE) and derivatives thereof for skin, hair care or cosmetic preparation. Also described is the use of compounds of formulas (I), (H) and (HI) and derivatives thereof to prevent or treat cellular and tissue damage caused by microbial pathogens secreting lipases. Described are pharmaceutical formulations comprising of any of compound of formulas (I), (Et) and (ID) and derivatives thereof by themselves or in conjunction with a suitable pharmaceutically acceptable excipient. Such formulations are useful in reducing or inhibiting activity of enzymes of lipase gene family participating in metabolism, absorption, and accumulation of lipids in body at various levels including body fluid, cellular and tissue level for treatment, amelioration or prevention of diseases mediated by lipase gene family enzymes such as overweight or obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, diabetes, atherosclerosis, other cardiovascular diseases, metabolic syndromes, and metabolic disorders. Also described is the manner of manufacture of medicaments comprising of compounds of formulas <T), (II) and (EI) and derivatives thereof in a, therapeutically effective amount either alone or in combination with pharmaceutically acceptable adjuvant. The compounds of formulas (I), (II) and (EI) and derivatives thereof may further be combined with other active ingredients. Also described is a method of treatment of diseases mediated by lipase gene family of enzymes by administering in a therapeutically effective amount any compound of formulas (I), (II) and (III) and derivatives thereof in human or animal subjects. 8 WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/W2005/000318 The present invention and other objects, features, and advantages of the present invention will become further apparent in the following Detailed Description of the Invention and the accompanying embodiments. DETAILED DESCRIPTION OF THE INVENTION Hie present invention provides novel compounds and compositions for use in reducing or inhibiting activity of lipase gene family enzymes for treatment, amelioration or prevention of lipase gene family enzyme mediated diseases and conditions in an individual. Definitions Unless otherwise specified the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein. The term "lipase gene family enzymes" as used herein include but are not limited to hepatic lipase; intestinal lipases including gastric lipase, pancreatic lipase, and carboxylester lipase; endothelial lipase; phospholipase and other related lipases. The term "pharmaceutically acceptable" as used herein refers to the substance including carrier, diluent, vehicle excipient, or composition being compatible chemically and/or toxicologically, with the other ingredients comprising a formulation that is not deleterious to the recipient thereof. The term "alkyl" by itself or as part of another substituent means, unless otherwise defined, a straight or branched chain monovalent hydrocarbon radical, such as for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, sec-butyl, n-pentyl andn-hexyl. The term, "alkenyl" employed alone or in combination with other terms means a straight chain or branched monovalent hydrocarbon group having the stated number ranges of carbon atoms, and groups such as vinyl, propenyl, crotonyl, isopentenyl, and various butenyl isomers. 9 RECEIVED at IPONZ on 16 December 2009 The term "comprising" as used in this specification means "consisting at least in part of'. When interpreting each statement in this specification that includes the term "comprising", features other than that or those prefaced by the term may also be present. Related terms such as "comprise" and "comprises" are to be interpreted in the same manner. 9a 565878 WO 2007/010546 PCT/IN2005/000318 The term, "alkynyl" employed alone or in combination with other terms means a straight chain or branched acyclic carbon chain which contains a carbon-to-carbon triple bond hydrocarbon group having the stated number ranges of carbon atoms, and groups. The term "cycloalkyl" means a cyclic either monocyclic or polycyclic alkyl radical having at least 3 carbon atoms and typically 3 to 7 carbon atoms. Examples are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The term "alkoxy", alone or in combination, signifies a group of the formula alkyl-O- in which the term "alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, 2° butoxy and 3° butoxy. or 2-methoxyethoxy. The term "Ci to C5 alkylcycloalkyl" means any of the Ci to C5 alkyl group is substituted on the cycloalkyl group and the composite group is attached to the nucleus at the alkyl terminus. The term "Ci to C6 heterocycloalkyl" means a heterocycloalkyl group having 2-6 carbon atoms, preferably 3-5 carbon atoms, and including at least one heteroatom selected from N, 0 and/or S, which may be attached via a heteroatom or a carbon atom. The term "aryl" means an aromatic hydrocarbon group having a single (e.g. phenyl) or a fused ring system (e.g. naphthalene, anthracene, phenanthrene, etc.). A typical aiyl group is aromatic caxbocylic ring having 6, 7, 8, 9 or 10 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl or indenyl, which may optionally be substituted with one or more substituents selected from hydroxy, amino, halogen, nitro, cyano, Q to C4 alkyl, C2 to C4 alkenyl, C2 to C4 alkynyl, Ci to C4 alkoxy, Ci to C4 dialkylamino, the alkyl moieties having the same meaning as previously defined. The preferred aromatic hydrocarbon group is phenyl. The term "C3 to C9 heteroaiyl" means a substituted or unsubstituted aromatic group having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, at least including one heteroatom selected from N, O and/or S, like imidazolyl, thiadiazolyl, pyridyl, (benzo)thienyl, (benzo)fiiryl, quinolyl, tetrahydroquinolyl, quinoxalyl or indolyl. The substituents on the heteroaiyl 10 565878 WO 2007/010546 PCT/IN2005/000318 group may be selected from the group of substituents listed for the aryl group. The heteroaryl group may be attached via a carbon atom or a heteroatom, if feasible. The term "Ce to Cio aryloxy" means an aryl group containing 6, 7, 8, 9, or 10 carbon atoms as defined previously, attached to an oxygen atom. C3 to C9 heteroaryloxy groups are analogs of the Cg to Cio aryloxy groups, at least including one heteroatom selected from N, O or S. The term "halo" means fluoro, chloro, bromo, or iodo. The term "amino", alone or in combination, signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, —NH2, methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-l-yl or piperidino etc., preferably amino, dimethylamino and diethylamino and particularly preferred primary amino. The term "cyano," alone or in combination, signifies a —CN group. The term "nitro," alone or in combination, signifies a—NO2 group. The term "heterocyclic group" refers to radicals or groups derived from monocyclic or polycyclic saturated or unsaturated, substituted or unsubstituted heterocyclic nuclei having 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms and containing 1, 2 to 3 hetero atoms selected from the group consisting of nitrogen, oxygen or sulfur. The term substituent is "non-interfering" substituents. By "non-interfering" is meant that the group is suitable chemically and stability wise to occupy the designated position and perform the designated or intended role. Thus unsuitable groups are excluded from the definition of "non-interfering". In addition, compounds of Formula (I) and derivatives thereof may be labeled with an isotope (e.g., 3H, I4C, 35S, 125I, etc.). A "prodrug" refers to a compounds capable of being converted to compounds of the present invention by reactions of an enzyme, gastric juice, or the like, under physiological conditions in vivo, specifically compounds capable of being converted to compounds of 11 565878 WO 2007/010546 PCT/IN2005/000318 the present invention upon enzymatic oxidation, reduction, hydrolysis, or the like, or a compounds capable of being converted to compounds of the present invention upon hydrolysis or the like by gastric juice or the like. A "polymorph" refers to a compound that occurs in two or more forms. The phrase "therapeutically effective amount" means an amount of a compound of the present invention that - treat or prevent the particular disease, condition, or disorder; or attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder; or prevents o delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein. The use of terms Ci -C„ is used to signify each of Ci, C2, C3, ... Cn. Thus, C1-C20 includes.Ci, C2, C3, C4, C5, C6, C7, Cs, C9, Cio, C11, C12, C13, Cu, C]5, Ci6, Cn, Cig, C19, and C20. Ci-Cl3 includes each of Ci, C2, C3, C4, Cs, Cg, C7, Cs, C9, Cio, Cn, C12,. C13. C2-C13 includes each of C2, C3, C4, C5, Cg, C7, Cg, C9, Cio, Cn, C12, C13, and so forth. It will be apparent that those skill in the art that any modifications, both to the materials and methods , may be practiced without departing from the purpose and interest of this invention. The following general terms as occurring in the examples are explained below: a) all operations carried out at room or ambient temperature were in the range of 1825 degree Centigrade b) the course of the reaction was monitored by thin layer chromatography (TLC) and reaction times are given for illustration only. c) Melting points are uncorrected, the melting ppoints are given for the materials prepared as described, polymorphism may result in isolation of materials with different melting points in some preparations. d) The structure and purity of all final products were assured by atleast one of the following techniques: TLC, NMR (nuclear magnetic resonance) spectroscopy, mass spectroscopy or microanalytical data. e) Yields are given for illustration only. 12 WO 2007/010546 PCT/IN2005/000318 f) When given, NMR data is in the form of delta (5) values for major diagnostic protons given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard determined at 300 MHz or 400 MHz using the indicated solvent. g) Chemical symbols have their usual meanings : the following abbreviations have also been used : v( volume), w (weight), B>p. 9 boiling point), Mp. (melting point), L ( litres) , ml (milliliters), gms ( grams), mg( milligrams), mol( moles) mmole(milli moles) , eq( equivalents), °C ( degree centigrade), conc. ( concentrated), SiC>2( silicon dioxide), NaaSCU ( sodium sulphate) h) The intermediates used in the following examples have been sourced from Sigma Lipases Three members of the human triacylglycerol lipase family have been described: pancreatic lipase, lipoprotein lipase, and hepatic lipase (Goldberg, I. J., Le, N.-A., Ginsberg, H. N., Krauss, R. M., and Lindgren, F. T. (1988) J. Clin. Invest. 81,561-568; Goldberg, I. J., Le, N., Paterniti J. R., Ginsberg, H. N., Lindgren, F. T., and Brown, W. V. (1982) J. Clin. Invest. 70,1184-1192; Hide, W. A., Chan, L., and Li, W.-H. (1992) J. Lipid. Res. 33,167-178). Pancreatic lipase is primarily responsible for the hydrolysis of dietary lipids. Variants of pancreatic lipase have been described, but their physiological role has not been determined (Giller, T., Buchwald, P., Blum-Kaelin, D., and Hunziker, W. (1992) J. Biol. Chem. 267,16509-16516). The lipase polypeptides encoded by these lipase genes are approximately 450 amino acids in length with leader signal peptides to facilitate secretion. The lipase proteins are comprised of two principal domains (Winkler, K., D'Arcy, A., and Hunziker, W. (1990) Nature 343, 771-774). The amino terminal domain contains the catalytic site while the carboxyl domain is believed to be responsible for substrate binding, cofactor association, and interaction with cell receptors (Wong, H., Davis, R. C., Nikazy, J., Seebart, K. E., and Schotz, M. C. (1991) Proc. Natl. Acad. Sci. USA 88,11290-11294; van Tilbeurgh, H., Roussel, A., Lalouel, J.-M., and Cambillau, C. (1994) J. Biol. Chem. 269,4626-4633; 565878 WO 2007/010546 PCT/IN2005/000318 Wong, H., Davis, R. C., Thuren, T., Goers, J. W., Nikazy, J., Waite, M., and Schotz, M. C. (1994) J. Biol. Chem. 269,10319-10323; Chappell, D. A., Inoue, I., Fry, G. L., Pladet, M. W., Bowen, S. L., Iverius, P.-H., Lalouel, J.-M., and Strickland, D. K. (1994) J. Biol. Chem. 269,18001-18006). The overall level of amino acid homology between members of the family is 22-65%, with local regions of high homology corresponding to structural homologies which are linked to enzymatic function. Members of the triacylglycerol lipase family share a number of conserved structural features. One such feature is the "GXSXG" motif, in which the central serine residue is one of the three residues comprising the "catalytic triad" (Winkler, K.., D'Arcy, A., and Hunziker, W. (1990) Nature 343, 771-774; Faustinella, F., Smith, L. C., and Chan, L. (1992) Biochemistry 31,7219-7223). Conserved aspartate and histidine residues make up the balance of the catalytic triad. A short span of 19-23 amino acids (the "lid region") forms an amphipathic helix structure and covers the catalytic pocket of the enzyme (Winkler, K., D'Arcy, A., and Hunziker, W. (1990) Nature 343, 771-774). Comparisons between hepatic and lipoprotein lipase have demonstrated that differences in triacylglycerol lipase and phospholipase activities of the enzymes are in part mediated by this lid region (Dugi, IC. A., Dichek H. L., and Santamarina-Fojo, S. (1995) J. Biol. Chem. 270, 25396-25401). Triacylglycerol lipases possess varying degrees of heparin binding activity. Lipoprotein lipase has the highest affinity for heparin, and this binding activity has been mapped to stretches of positively charged residues in the amino terminal domain (Ma, Y., Henderson, H. E., Liu, M.-S., Zhang, H., Forsythe, I. J., Clarke-Lewis, I., Hayden, M. R., and Brunzell, J. D. J. Lipid Res. 35,2049-2059). The genetic sequences encoding human pancreatic lipase, hepatic lipase and lipoprotein lipase have been reported (GenBank accession #M93285, #J03540, and #M15856 respectively). The messenger RNAs of human hepatic lipase and pancreatic lipase are approximately 1.7 and 1.8 kilobases in length respectively. Two mRNA transcripts of 3.6 and 3.2 kilobases are produced from the human lipoprotein lipase gene. (Ranganathan, G., Ong, J. M., Yukht, A.; Saghizadeh, M., Simsolo, R. B., Pauer, A., and Kern, P. A. (1995) J. Biol. Chem. 270, 7149-7155). 14 565878 RECEIVED at IPONZ on 26 March 2010 Compounds that affect lipase activity The present invention provides a use of a compound selected from 2,5-dihydroxy-3-undecyl-p-benzoquinine, the compounds of any one of formulae (I), (II) and (III), optical isomers thereof, polymorphs thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of said compounds, said isomers or said polymorphs, all solvates and hydrates thereof and all salts thereof, in the manufacture of a medicament for use in a method for treatment, amelioration or prevention of a disease or condition mediated by a lipase gene family enzyme comprising inhibiting or reducing activity of an enzyme belonging to lipase gene family to an extent that treats, ameliorates or prevents the disease or condition wherein Ri and R2 are each independently selected from the group consisting of hydrogen, C3-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 arylamine, C(0)Ci-Ce alkyl, 0-C(0)Ci-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, C(0)aryl and 0-C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that Rt and R2 are not phenyl; O O (II) 0 15 RECEIVED at IPONZ on 16 December 2009 wherein R/ and R27 are each independently selected from the group consisting of C3-C13 alkyl, C1-C20 haloalkyl, C2-Ci3 alkenyl, C2-Ci3 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 arylamine, C(0)Ci-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C|-Q alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that R/ and R2 are not wherein R/' and R2" are each independently selected from the group consisting of hydrogen, C1-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C13 alkylamine, C1-C13 arylamine, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C(0)Ci-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups. Also described are compounds of formula (I): phenyl; O 0 0 15a 565878 RECEIVED at IPONZ on 16 December 2009 and derivatives thereof including but not limited to polymorphs, isomers and prodrugs thereof geometric or optical isomers thereof; and pharmaceutically acceptable esters, ethers, carbamates of such compounds, all solvates and hydrates thereof and all salts thereof, wherein: Ri and Ra are each independently selected from the group consisting of hydrogen, C3-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-Q cycloalkenyl, C1-C13 alkoxyalkyl, Ci-Cs alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 arylamine, C(0)Ci-C6 alkyl, 0-C(0)CrC6 alkyl, heterocycloalkyl, aryl, alkylaryl, C(0)aiyl and 0-C(0)aiyl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aiyl, alkoxy, and aryloxy groups. However in accordance with the present invention Ri and Ra are not methyl, methoxy, ethyl, ethoxy, phenyl, and hydroxy. Also described are compounds of formula (II): and derivatives thereof including but not limited to polymorphs, isomers and prodrugs thereof, geometric or optical isomers thereof and pharmaceutically acceptable esters, ethers, carbamates of such compounds, all solvates and hydrates thereof and all salts thereof, wherein: Ri and R2 are each independently selected from the group consisting'of O 0 15b WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 C3-C13 alkyl, C1-C20 haloalkyl, C2-Cl3 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C5 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 aiylamine, C(0)Ci-C6 alkyl, heterocycloalkyl, aiyl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, Ci-Q alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups. However in accordance with the present invention Ri and R2 are not methyl, ethyl, and phenyl. Also described are compounds of formula (III): and derivatives thereof including but not limited to polymorphs, isomers and prodrugs thereof, geometric or optical isomers thereof, and pharmaceutically acceptable esters, ethers, carbamates of such compounds, all solvates and hydrates thereof and all salts thereof, wherein: Rl and R2 are each independently selected from the group consisting of hydrogen, C1-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C5 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C13 alkylamine, C1-C13 arylamine, C1-C5 alkylcycloalkyl, Ci-Cs alkylcycloalkenyl, C(0)Ci-Cg alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aiyl, alkoxy, and aryloxy groups. In one embodiment compounds of Formula (HI) have Ri and R2 independently selected from C(0)aiyl, C(0)alkylaiyl, C(0)haloaryl, C(0)nitroaxyll, or C(0)alkoxyaryl. Other embodiments relate to compounds of Formula (HI), wherein Ri and Ra are independently selected from methyphenylcaibonyl, ethylphenylcarbonyl, propylphenylcarbonyl, butylphenylcarbonyl, chlorophenylcarbonyl, O 10 o 16 565878 WO 2007/010546 PCT/IN2005/000318 bromopheynylcabonyl, iodophenylcarbonyl, fluorophenylcarbonyl, nitrophenylcarbonyl, methoxyphenylcarbonyl, or ethoxypheny lcarbonyl. Further embodiments relate to compounds of Formula (III), wherein Ri and R2 are independently selected from 2-methyphenylcarbonyl, 3-methyphenylcarbonyl, 4-methyphenylcarbonyl, 4-ter-butylphenylcarbonyl, 2-chlorophenylcarbonyl, 3-chlorophenylcarbonyl, 4-chlorophenylcarbonyl, 2-bro mopheynylcabony 1, 3- bromopheynylcabonyl, 4-bromopheynylcabonyl, 2-iodophenylcarbonyl, 3-iodophenylcarbonyl, 4-iodophenylcarbonyl, 2-fluorophenylcarbonyl, 3-fluorophenylcarbonyl, 4-fluorophenylcarbonyl, 2-nitrophenylcarbonyl, 3- nitrophenylcarbonyl, 4-nitrophenylcarbonyl, 2-methoxyphenylcarbonyl, 3-methoxyphenylcarbonyl, and 4-methoxyphenylcarbonvl. Accordingly, the present invention also encompasses prodrugs of compounds of the present invention. The term "prodrug" includes a compound that is transformed in vivo to yield a compound of Formulas (I), (II) or (III). Information about the use of prodrugs may be found in "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, by T. Higuchi and W. Stella, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987. Suitable active metabolites of compounds within the scope of Formulas (I), (II) or (III), in any suitable form, are also included herein. The compounds of the present invention may contain asymmetric or chiral centers, and therefore may exist in different stereoisomeric forms. All suitable optical isomers and stereoisomeric forms of the compounds of the present invention as well as mixtures thereof, including racemic mixtures, form part of the present invention. In addition, the present invention embraces all geometric and positional isomers. For example, if a compound of the present invention incorporates a double bond or a fused ring, the cis-and trans-forms, as well as mixtures, are embraced within the scope of the invention. With respect to such compounds, the present invention includes the use of a racemate, a single enantiomeric form, a single diastereomeric form, or mixtures thereof, as suitable. Moreover, such compounds may also exist as tautomers. Accordingly, the present 17 565878 WO 2007/010546 PCT/IN2005/000318 invention relates to the use of all such suitable tautomers and mixtures thereof. Diastereomeric mixtures can be separated into their individual diastereoisomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as by chromatography and/or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereoisomers and converting (e.g., hydrolyzing) the individual diastereoisomers to the corresponding pure enantiomers or by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase. Also, some of the compounds of the present invention may be atropisomers (e.g., substituted biaryls) and are considered as part of this invention. Enantiomers can also be separated by use of a chiral HPLC column. Moreover, some compounds of the present invention may exhibit polymorphism. The scope of the present invention includes all polymorphic forms of the compounds according to the invention, which forms the further aspect of the invention. It is to be understood that the present invention encompasses any and all racemic, optically-active, polymorphic and stereoisomeric forms, or mixtures thereof, which form or forms possess properties useful in the treatment of the conditions indicated herein. Furthermore, the present invention also include isotopically-labeled compounds of the present invention which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2H, 3H, llC3 l3C, l4C, l3N, 15N, 150,170, l80,31P, 32P, 35S, l8F? 1231, 125I and 36C1, respectively. Certain isotopically-labeled compounds of the present invention (e.g., those labeled with. 3H and. 14C) are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e.,. 3H) and carbon-14 (i.e., 14C) isotopes are particularly preferred for their ease of preparation and delegability. Further, substitution with heavier isotopes such as deuterium (i.e.,2H) may afford certain therapeutic advantages resulting from greater 18 WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/1N2005/000318 metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances. Positron emitting isotopes such as 150, 13N, hC, and l8F are useful for positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds of the present invention can generally be prepared by procedures analogous to those disclosed in the Examples herein below, by substituting an isotopically labeled reagent for a non-isotopically labeled reagent. Also described is a process for preparing compounds of Formulas (I), (II) or (HI). Those skilled in the art will understand from this disclosure how to prepare the most preferred compounds of the present invention using any suitable known method. Compounds of Formulas (I), (II) or (HI) and, unless otherwise indicated, Ri, R2, as described above may be conveniently prepared according to Scheme I. In addition, the examples provided herein further illustrate the preparation of the compounds of the present invention. Moreover, those skilled in the art will understand from the present disclosure how to modify Scheme I, and the details of the examples described hereinafter to prepare any specific compound of Formulas (I), (II) or (III) of the present invention as desired. It should be understood that Scheme I is provided solely for the purposes of illustration and depicts potential route for synthesizing compounds of Formulas (I), (II) or (HI) and does not limit the invention. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds of the present invention. Although specific starting materials and reagents are depicted in the Scheme I illustrated below, the suitable substitution can be easily made to provide a variety of derivatives and reaction conditions. In addition, many of the compounds prepared by the method described below can be further modified in light of the disclosure using the conventional chemistry known to those skilled in the art. 19 WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 Scheme I: O HO^V><0 oh2ci* II 10 Temperature 1 [j q 0 Co-solvent O JL^OH o Co-solvent Scheme I depicts a genera] protocol for preparing compound of Formulas (I), (II) or (HI) starting from 2,5-dihydroxy-3-undecyI-l,4-benzoquinone or its oxime, or substituted oxime, or suitable salt or analogs thereof. The starting material - 2,5-dihydroxy-3-undecyl-1,4-benzoquinone - is reacted with alkyl chloride or acyl chloride, or aiyl chloride or aroyl chloride, or substituted aryl chloride or substituted aroyl chloride in a suitable inert halogenated solvent (e.g. dichloromethane) in presence of a suitable aromatic base (e.g. pyridine) under the controlled condition such as at a temperature of about 10°C to about 40°C over a period of about 1 hour to about 24 hours to yield the compound of Formulas (I), (II) or (HI) in crude form. Conventional methods and/or techniques of separation and purification known to one of ordinary skill in the art can be used to isolate & purify the compounds of the present invention. Such techniques will be well known to one of ordinary skill in the art and may include, for example, all types of chromatography (high pressure liquid chromatography (HPLC), column chromatography using common adsorbents such as silica gel, and thin-layer chromatography), recrystallization, and differential (i.e., liquid-liquid) extraction techniques. Lipase related diseases and conditions It is an aspect of the present invention to provide compounds of Formulas (la), (Ila) or (Ilia) and derivatives thereof for use as therapeutically active substances. The compounds of the present invention as disclosed above are useful for reducing or inhibiting activity of lipase gene family enzymes for treatment, amelioration or prevention of lipase gene family enzyme mediated diseases. The compounds are useful in reducing or inhibiting metabolism, absorption, and accumulation of fat at various levels 20 WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 including body fluid, cellular, and tissue levels in body by inhibiting or reducing the activity of enzymes belonging to lipase gene family. Thus, the compounds of the present inventions and derivatives thereof including compositions thereof are useful in reducing or inhibiting activity of enzymes of lipase gene family participating in metabolism, absorption, and accumulation of lipids in body at various levels including body fluid, cellular and tissue level for treatment, amelioration or prevention of diseases mediated by lipase gene family enzyme including but not limited to overweight or obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, hyperglycemia, atherosclerosis, metabolic syndromes, other cardiovascular diseases, and other metabolic disorders. In another aspect the compounds of the present invention and derivatives thereof including compositions thereof are useful in prevent or treat cellular and tissue damage caused by microbial pathogens secreting lipases. In another aspect the compounds of the present invention and derivatives thereof including compositions thereof are also useful for skin, hair care or cosmetic preparation. Also described is a method for treating conditions, diseases and/or disorders mediated by enzymes belonging to the lipase gene family including but not limited to overweight or obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, hyperglycemia, atherosclerosis, metabolic syndromes, other cardiovascular diseases, and other metabolic disorders by reducing or inhibiting metabolism, absorption, and accumulation of fat at various levels including body fluid, cellular, and tissue levels in body by inhibiting or reducing the activity of enzymes belonging to lipase gene family in mammal including a human being which comprises administering to said mammal an effective treating amount of a compound of Formulas (I), (H) or (ET) or derivatives thereof. Also described is a method for treating or preventing cellular and tissue damage caused by microbial pathogens secreting lipases by inhibiting or reducing the activity of enzymes belonging to lipase gene family in mammal including a human being which comprises administering to said mammal an effective treating amount of a compound of Formulas (I), (II) or (HI) or derivatives thereof. 21 WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 Accordingly it is one embodiment of the present invention to provide a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formulas (la), (Ila) or (Ilia) or a derivative thereof and a pharmaceutically acceptable inert adjuvant, diluent or carrier. Alternatively a pharmaceutical composition may comprise of at least one additional pharmaceutically active agent. Additional active pharmaceutical agent may be selected from chemically synthesized compounds or those derived from natural origin having desired pharmacological activity. Formulations A compound of Formulas (la), (Ha) or (Ilia) or a derivative thereof can be administered in any conventional oral, buccal, nasal, by inhalation spray in unit dosage form, parenteral, (for example, intravenous, intramuscular, subcutaneous intrastemal or by infusion techniques), topical (for example, powder, ointment or drop), "transdermal, intracistemal, intravaginal, intraperitoneal, intravesical, or rectal,. In another aspect of the invention, the compound of the present invention and at least one other pharmaceutically active agent may be administered either separately or in the pharmaceutical composition comprising both. It is generally preferred that such administration be oral. However, if the subject being treated is unable to swallow, or oral administration is otherwise impaired or undesirable, parenteral or transdermal administration may be appropriate. A compound of Formulas (la), (Ha) or (Ilia) or a derivative thereof can be administered in the form of any modified release, controlled release or timed release formulations, (see, e.g., Langer, Science 249:1527-1533 (1990)). In one embodiment, a pump can be used (Langer, Science 249:1527-1533 (1990); Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); and Saudek et al., N. Engl. J. Med. 321:574 (1989)). In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release (Langer and Wise eds., 1974); Controlled Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds., 1984); Ranger and Peppas, J. Macromol. Sci. Rev. Macromol. Chem. 23:61 (1983); Levy et al., Science 228:190 (1985); During et al., Ann. Neurol. 25:351 (1989); and Howard et al., J. Neurosurg. 71:105 (1989)). 22 WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 The dose of a compound of Formula (la), (Da) or (Ilia) or derivatives thereof to be administered to a mammal including human or animal for the purposes as mentioned above is not specifically limited. Rather it is widely variable and subject to the pathologies, conditions, symptoms, or age of the subject and judgment of the attending physician or veterinarian. The general range of effective administration rates of the compounds of the present invention is from about 0.001 mg/kg body weight to about 100 mg/kg body weight of the subject per day. A preferred range of effective administration rates of the compounds of this invention is from about 0.01 mg/kg body weight to about 50 mg/kg body weight of the subject per day. Amounts are selected based on various factors, including the milieu to which the composition is administered, the site of the cells to be treated, the age, health, gender, and weight of a patient or animal to be treated, etc. Useful amounts include, 1,5, 15,20,25, 30, 40, 60, 150,200 milligrams, 1 gm, 2 gm, 3 gm, and ranges between 10 milligrams-100 grams, 50 milligrams - 5 grams, 100 milligrams-10 grams, 250 milligrams-2.5 grams, 500 milligrams-1.25 grams, etc., per dosage. While it may be practical to administer the daily dose of a compound of tills invention, in portions, at various hours of the day, in any given case, the amount of compound of this invention will depend on such factors as the solubility of the compound, prodrug, isomer or pharmaceutically acceptable salt of this invention, the formulation used and the route of administration (e.g., orally, transdetmally, parenterally or topically). Dosages of the compounds of the present invention can be administered to humans by any suitable route, with oral administration being preferable. Individual oral dosage form for example, tablets or capsules should generally contain from about 0.1 mg to about 100 mg of compound of this invention, in a suitable pharmaceutically acceptable vehicle, diluent or carrier. Dosages for intravenous administration are generally within the range of from about 0.1 mg to about 10 rag per single dose as required. For intranasal or inhaler administration, the dosage is generally formulated as from about a 0.1% to about a 1% (w/v) solution. In practice, the physician will determine the actual dosage, which will be most suitable for an individual patient, and it will vary with, e.g., age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can, of course, be individual instances where higher or lower dosage ranges are 23 WO 2007/010546 565878 RECEIVED at IPONZ on 16 December 2009 PCT/IN2005/000318 possible, such dosages of compounds of this invention, are within the scope of the present invention. It is another preferred embodiment' of the present invention to provide compounds of Formulas (la), (Ila) or (Ilia) and derivatives thereof for manufacturing pharmaceutical formulations for the prophylaxis and therapy of conditions, diseases and/or disorders mediated by enzymes belonging to the lipase gene family including but not limited to overweight or obesity, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, pancreatitis, hyperglycemia, atherosclerosis, metabolic syndromes, other cardiovascular diseases, and other metabolic disorders. The pharmaceutical formulation comprising a compound of Formulas (la), (Ila) or (Ilia) or the derivatives thereof may be formulated in a conventional manner known to those skilled at the art using one or more pharmaceutically acceptable diluent, carrier, or vehicle. For oral administration the pharmaceutical formulations that may be used in the present invention include tablets, chewable tablets, controlled release tablets, capsules, lozenges, granules, powders, pills, microcapsules, elixirs, syrups, and suspensions. In general tablets can be prepared by methods known in pharmaceutical science by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as a compound of this invention. Common diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives may also be used. Common tablet binders include substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpynolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders. A lubricant is generally necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils. Tablet disintegrators include substances, which swell when wetted to break up the tablet and release a compound, prodrug, isomer or pharmaceutically acceptable salt of this 24 565878 WO 2007/010546 PCT/IN2005/000318 invention. They include starches, clays, celluloses, algins and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used as well as sodium lauryl sulfate. Tablets are often coated with sugar as a flavor and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet. The compounds of the invention may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established in the art. As discussed above, the effect of a compound of this invention may be controlled that is delayed or prolonged or time bound by proper formulation. For example, a slowly soluble pellet of a compound of this invention may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates with subsequent filling the mixture of these pellets in capsules. Tablets or capsules may be coated with a film, which resists dissolution for a predictable period of time. Capsules can be prepared by mixing a compound of the invention with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending/viscosity enhancing agents (e.g. sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters or ethyl alcohol, medium chain triglycerides); and preservatives (e.g. methyl or propyl p-hydroxybenzoates or sorbic acid). 25 565878 WO 2007/010546 PCT/IN2005/000318 For parenteral administration the compounds of the invention may be formulated in the form of an injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. The injectable solutions or suspensions may be formulated according to known art, using suitable non-toxic, parenterally-acceptable diluents or solvents, such as mannitol, 1,3-butanediol, water, Ringer's solution or isotonic sodium chloride solution, or suitable dispersing or wetting and suspending agents, such as sterile, bland, fixed oils, including synthetic mono- or diglycerides, and fatty acids, including oleic acid and surfactants such as, for example, hydroxypropyl cellulose, also the pH of the solution being suitably adjusted and buffered, where necessary. Generally oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. Such aqueous solutions are suitable for intravenous injection purposes. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use. The parenteral preparations may also be made long-acting by dissolving or suspending a compound, prodrug, isomer or pharmaceutically acceptable salt of this invention, as the case may be, in oily or emulsified vehicles which allow it to disperse only slowly in the serum. For intranasal administration or administration by inhalation, the compounds of the present invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, triehl oro fl uoro methane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. When administered by nasal aerosol or inhalation, these compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl 26 565878 WO 2007/010546 PCT/IN2005/000318 alcohol or other suitable preservatives, absoiption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable , powder for inhalation base such as lactose or starch. The compounds of this invention may also be administered topically and this may be done by way of, e.g., creams, jellies, salves, lotions, gels, pastes, ointments, and the like, in accordance with standard pharmaceutical practice. The compounds of the present invention may also be administered transdermally (e.g., through the use of a patch). Any suitable formulation for transdermal application comprising a compound of the present invention may be employed and such formulations would generally also contain a suitable transdermal carrier, e.g., an absorbable pharmacologically acceptable solvent to promote and assist passage of the compounds through the subject's skin. For example, suitable transdermal devices may comprise the form of a bandage having a backing member and a reservoir containing the subject compound. Such bandage-type transdermal devices may further include suitable carriers, rate-controlling barriers, and means for securing the transdermal device to the subject's skin. Where it is desired to administer a compound of this invention as a suppositoiy, any suitable base can be used. Cocoa butter is a traditional suppositoiy base, which may be modified by the addition of waxes to raise its melting point. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use. In other embodiments a compound of this invention may be incorporated in food, or beverages. The compounds of this invention may also be administered to a mammal other than a human. The method of administration and the dosage to be administered to such a mammal will depend, for example, on the animal species and the disease or disorder being treated. The compounds of this invention may be administered to animals in any suitable manner, e.g., orally, parenteral!)' or transdermally, in any suitable form such as, for example, a capsule, bolus, tablet, pellet, e.g., prepared by admixing a compound, 27 WO 2007/010546 PCT/IN2005/000318 prodrug, isomer or pharmaceutically acceptable salt of this invention with a suitable diluent such as carbowax or carnuba wax together with a lubricant, liquid drench or paste, e.g., prepared by dispersing a compound of this invention in a pharmaceutically acceptable oil such as peanut oil, sesame oil or corn oil. The compounds, prodrugs, isomers or pharmaceutically acceptable salts of this invention may also be administered to animals as an implant. Such formulations are prepared in a conventional manner in accordance with standard veterinary practice. As an alternative, the compounds of this invention may be administered with the water supply, e.g., in the form of a liquid or water-soluble concentrate. In addition, the compounds of this invention, e.g., within the pharmaceutical compositions of the invention, may be administered in the animal feedstuff, e.g., a concentrated feed additive or premix may be prepared for mixing with the normal animal feed, commonly along with a suitable carrier therefore. The carrier facilitates uniform distribution of the compound, prodrug, isomer or pharmaceutically acceptable salt of this invention in the, e.g., finished feed with which the premix is blended. Suitable carriers include, but are not limited to, liquids, e.g., water, oils such as soybean, corn, cottonseed, or volatile organic solvents, and solids, e.g., a small portion of the feed or various suitable meals including alfalfa, soybean, cottonseed oil, linseed oil, corncob, corn, molasses, urea and bone, and mineral mixes. In another aspect of the present invention the biological assays carried out using compounds of Formulas (I), (II) and (III) demonstrate potent inhibition of lipases. The following examples illustrate the embodiments of the present invention. It is to be understood, however, that the embodiments of the invention are not limited to the specific details of these Examples, as other variations thereof will be known, or apparent in light of the instant disclosure, to one of ordinary skill in the art 565878 WO 2007/010546 PCT/IN2005/000318 EXAMPLES Example 1: Extraction and isolation of the starting material: 2,5-dihydroxy-3-undecyl-l ,4-benzoquinone O Structure # 1 2,5-Dihydroxy-3-undecyl-p-benzoquinone (embelin) Powdered berries of Embelia ribes were extracted successively with petroleum ether, chloroform, ethyl acetate, methanol and water. The chloroform extract was subjected to repeated crystallization using petroleum ether as the crystallizing solvent. The crystallization step was repeated to increase the yield. The mother liquor was fractionated by silica gel column chromatography (100-200 mesh) using petroleum ether-chloroform as the eluting solvents (gradient elution) to further improve the yield. All fractions were monitored on Silica gel TLC plates (Silica gel 60 F254, Merck) with n-propanol:n-Butanol:liquor ammonia (6:1:3) as the TLC solvent system. On the basis of TLC, similar fractions were pooled together & concentrated under reduced pressure. The compound was purified by repeated ciystallization in petroleum ether to yield 140 g (3.5%) of extract. About 50 g of extract was refluxed in petroleum ether (500 ml) until the extract dissolved in the solvent. The solution was cooled to room temperature and filtered. The above procedure was repeated until compound of desired purity was obtained. The resultant compound showed 'H NMR (300 MHz, CDCI3) 8: 0.87 (m, 3H), 1.0 - 1.75 (m, 18H), 2.43 (m, 2H), 5.99 (s, 1H), 7.66 (bs, 2H). TOF MS ES: 295 (M + H). Mp. 142-143°C. HO O 29 565878 WO 2007/010546 PCT/IN2005/000318 Example 2: 2,5-Di-<?-(3-fluorophenylcarbonyl)-3-undecyI-l,4-benzoquinone F Synthesis of Structure # 2; 2,5-6 ;a-(3 -fluorophenylcarb onylan')-3 -undecy 1-1,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 rnL, 13.6 mmole). To this, was added 3-fluoro benzoylchloride (1.35 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2SC>4), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to a pure mass (0.96 g, 52.7%). !H NMR (300 MHz, CDCI3) 5: 0.87 (t, 3H, J = 6.9 Hz), 1.0-1.6 (m, 18H), 2.5 (t, 2H, J = 7.6 Hz), 6.8 (s, 1H), 7.3 - 8.0 (m, 8H). TOFMS ES: 539 (M + H). Mp. 73.2 - 75.6 °C. 30 565878 WO 2007/010546 PCT/IN2005/000318 Example 3: 2,5-Di-0-(4-tert-butylphenyl carbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure# 3; 2,5-&z's-(4-tert-butylphcnylcarbonylo.ry)-3-Lmdecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 4-tert-butyl benzoylchloride (1.67 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to a pure mass (1.47 g, 28.3%). ]H NMR (300 MHz, CDC13) 5: 0.86 (t, 3H, J = 7.0 Hz), 1.0-1.6 (m, 36H), 2.5 (t, 2H, J = 7.5Hz), 6.75 (s, 1H), 7.4 - 8.2 (m, 8H). TOF MS ES: 615 (M + H). Viscous mass. 31 565878 WO 2007/010546 PCT/IN2005/000318 Example 4: 2,5-Di-<?-(2-fluorophenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure # 4; 2,5-&z's-(2-fluorophenylcarbonyl ox>')-3-undecyl-l ,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benz;oquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 2-fluoro benzoylchloride (1.35 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2SC>4), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to a pure mass (0.96 g, 52.7%). 'H NMR. (300 MHz, CDC13) 5: 0.87 (t, 3H, J = 6.9 Hz), 1.1 - 1.7 (m, 18H), 2.5 (t, 2H, J = 8.0 Hz), 6.8 (s, 1H), 7.2 - 8.2 (m, 8H). TOF MS ES: 539 (M + H). Mp. 66.2 - 68 °C. Example 5: 2,5-Di-0-(2-bromophenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure # 5; 2,5-iw-(2-bromophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (l.Ogm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was O 32 565878 WO 2007/010546 PCT/IN2005/000318 added 2-bromobenzoyl chloride (1.9 g, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to pure mass (1.56 g, 69.6%). 'HNMR (400 MHz, CDCI3) 5: 0.87 (t, 3H, J = 6.8 Hz), 1.0 - 1.8 (m, 18H), 2.5 (t, 2H, J = 6.8 Hz), 6.8 (s, 1H), 7.4 - 8.2 (m, 8H). TOF MS ES: 680 (25, M1" + Na), 682 (100, M* + 2 + Na), 684 (25, M+ + 4 + Na). Mp. 77.1-78.6 °C Example 6: 2.5-Di-0-(3-bromophenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure # 6; 2,5-&z£-(3-bromophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 g, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 3-bromobenzoyl chloride (1.9 g, 8.5 mmole) at 15-20 °C and stined, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to pure mass (1.4 g, 62%). !H NMR (400 MHz, CDCI3) 5: 0.87 (t, 3H, J = 7.2 Hz), 1.0-1.8 (m, 18H), 2.51 (t, 2H, J = 7.2 Hz), 6.8 (s, 1H), 7.4 - 8.4 (m, 8H). TOF MS ES: 680 (5, M1" + Na), 682 (20, M* + 2 + Na), 684 (5, M1" + 4 + Na). Mp. 98.2-99.6 °C O o o 33 565878 WO 2007/010546 PCT/IN2005/000318 Example 7: 2,5-Di-0-(3-chlorophenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure # 7; 2,5-^w-(3-chlorophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 3-chloro benzoyl chloride (1.5 gm, 8.50 mmole) at 15- 20 °C and stirred, allowed to attain 30 C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to pure mass (1.25 g. 64.4%) *H NMR (300 MHz, CDC13) 5: 0.87 (t, 3H, J = 6.9 Hz), 1.1 - 1.7 (m, 18H), 2.5 (t, 2H, J = 7.6 Hz), 6.8 (s, 1H), 7.4 - 8.2 (m, 8H). TOF MS ES: 593 (9, M1" + Na), 595 (3, M^ + 2 + Na). Mp. 102.8-104.6 °C Example 8: 2,5-Di-0-(2-chlorophenylcarbonyl)-3-undecyI-l,4-benzoquinone Synthesis of Structure # 8; 2,5-&w-(2-chlorophenylcarbonylory)-3-undecyl-l,4-benzoquinone. CI CI 34 565878 WO 2007/010546 PCT/IN2005/000318 To a stirred solution of 255-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 2-chloro benzoyl chloride (1.5 gm, 8.50 mmole) at 15 —20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (NaiSCU), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to pure mass (1.14 g, 58.7%). 'H NMR (300 MHz, CDC13) 8: 0.87 (t, 3H, J = 6.9 Hz), 1.0-1.6 (m, 18H), 2.5 (t, 2H, J = 8.0 Hz), 6.8 (s, 1H), 7.2 - 8.2 (m, 8H). TOF MS ES: 593 (100, M4 + Na), 595 (35, M4" + 2 + Na). Mp. 56.2-57.8 °C Example 9: 2,5-Di-(?-(4-chlorophenyIcarbonyI)-3-undecyI-l,4-benzoqumone Synthesis of Structure # 9; 2,5-&i£-(4-chlorophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (l.Ogm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 4-chloro benzoyl chloride (1.5 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by SiOa column chromatography (10-20% EtOAc in hexane) to pure mass (1.21 g, 62.4%).. ]H NMR (400 MHz, CDC13) 8: 0.87 (t, 3H, J = 7.0 Hz), 1.1 - 1.7 (m, 18H), 2.5 (t, 2H, J = 7.6 Hz), 6.8 (s, 1H), 7.3 - 8.1 (m, 8H). TOF MS ES: 593 (10, M4 + Na), 595 (3, M+ + 2 + Na).Mp. 110.2-112 °C O O O 35 WO 2007/010546 565878 PCT/IN2005/000318 Example 10: 2,5-Di-0-(4-bromophenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure # 10; 2,5-&z'5-(4-bromophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 g, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 4-bromobenzoyl chloride (1.9 g, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to pure mass (1.49 g, 66.5%). !H NMR (400 MHz, CDC13) 8: 0.8 (t, 3H, J = 6.8 Hz), 1.0-1.8 (m, 18H), 2.5 (t, 2H, J = 7.6 Hz), 6.7 (s, 1H), 7.6 - 8.2 (m, 8H). TOF MS ES: 680 (5, lyt + Na), 682 (20, M* + 2 + Na), 684 (5, ^ + 4 + Na). Mp. 124.4-126.7 °C Example 11: 2,5-Di-0-(3-nitrophenylcarbonyl)-3-undecyl-l,4-benzoquinone V/ 10 N°2 O. Synthesis of Structure # 11; 2,5-£w-(3-nitrophenylcarbonyloxy)-3 -undecyl-1,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was 36 565878 WO 2007/010546 PCT/IN2005/000318 added 3-nitro benzoyl chloride (1.6 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2SC>4), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to a pure mass (0.95 g, 47%). NMR (300 MHz, CDC13) 5: 0.86 (t, 3H, J = 6.9 Hz), 1.1 - 1.6 (m, 18H), 2.5 (t, 2H, J = 8.0 Hz), 6.8 (s, 1H), 7.6-8.6 (m, 8H). TOF MS ES: 593 (M+H). Mp. 112.6 - 114.4 °C. Example 12: 2,5-Di-0(4-methyIphenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure # 12; 2,5-Z>z's-(4-methylphenylcarbonyloxj;)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (0.15 g, 0.5 mmole) in dichloromethane (20 mL) was added pyridine (0.41 mL, 5.1 mmole). To this, was added 4-toluoyl chloride (0.23 g, 1.53 mmole) at 15- 20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3.5 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexanes) to pure mass (84 mg, 32%). *H NMR (300 MHz, CDC13) 5: 0.85 (m, 3H), 1.0 - 1.8 (m, 18H), 2.44 (m, 8H), 6.74 (s, 1H), 7.25 - 8.25 (m, 8H). TOF MS ES: 553 (100, M1" + Na). Mp. 94.8-96. 2°C. O O O 37 565878 WO 2007/010546 PCT/IN2005/000318 Example 13: 2,5-Di-0-(3-methylphenylcarbonyl)-3-uridecyl-l,4-benzoquinone Synthesis of Structure # 1-3; 2,5 -bis-Q-methylphenylcarbonylorv)-3-undecyl-1,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (0.5 g, 1.7 mmole) in dichloromethane (20 mL) was added pyridine (0.55 mL, 6.8 mmole). To this, was added 3-toluoyl chloride (0.654 gm, 4.25 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by S1O2 column chromatography (10-20% EtOAc in hexane) to pure mass (0.64 g, 71%). !H NMR (300 MHz, CDC13) 5: 0.85 (t, 3H, J = 7.5 Hz), 1.0-1.5 (m, 18H), 2.3 - 2.5 (m, 8H), 6.75 (s, 1H), 7.30 - 7.61 (m, 5H), 7.9 - 8.10 (m, 3H). TOF MS ES: 553 (100, M+ + Na). Mp. 80.4-81.7 °C Example 14: 2,5-Di-0-(2-nitrophenylcarbonyl)-3-undecyl-l,4-benzoquinone N02 Synthesis of Structure # 14; 2,5-&w-(2-nitrophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone. 38 565878 WO 2007/010546 PCT/IN2005/000318 To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 2-nitro benzoyl chloride (1.6 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by SiC>2 column chromatography (10-20% EtOAc in hexane) to a pure mass (0.95 g, 47%). !H NMR (400 MHz, CDC13) 5: 0.86 (t, 3H, J = 6.5 Hz), 1.1 - 1.6 (m, 18H), 2.6 (t, 2H, J = 8.0 Hz), 6.9 (s, 1H), 7.7 - 8.1 (m, 8H). TOF MS ES: 615 (100, M4 + Na). Mp. 72.2-73.8 °C Example 15: 2,5-Di-0-(phenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure #15; 2,5-6i's-(phenylcarbonyloxv)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (0.3 g, 1.02 mmole) in dichloromethane (20 mL) was added pyridine (0.3 mL, 4.08 mmole). To this, was added benzoyl chloride (0.26 gm, 2.55 mmole) at 15 — 20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexanes) to pure mass (0.285 g, 56.8%). *H NMR (400 MHz, CDC13) 5: 0.85 (m, 3H), 1.10 - 1.68 (m, 18H), 2.50 (m, 2H), 6.77 (s, 1H), 7.42 - 7.64 (m, 6H), 8.11 - 8.22 (m, 4H). TOF MS ES: 525 (100, M* + Na). Mp. 98.2-99.6 °C. O O O 39 565878 WO 2007/010546 PCT/IN2005/000318 Example 16: 2,5-Di-0-(4-fluorophenylcarbonyl)-3-undecyl-l,4-benzoquinone Synthesis of Structure # 16; 2,5-Z>zs-(4-fluorophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 4-fluoro benzoylchloride (1.35 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to a pure mass (0.85 g, 46.4%). !H NMR (400 MHz, CDC13) 5: 0.86 (t, 3H, J = 6.7 Hz), 1.0-1.7 (m, 18H), 2.5 (t, 2H, J = 7.3 Hz), 6.7 (s, 1H), 7.1 - 7.2 (m, 4H), 8.1 - 8.2 (m, 4H). Mp. 95.8-97.7 °C Example 17: 2,5-Di-0-(3-methoxyphenylcarbonyl)-3-undecyl-l,4-benzoquinone OMe Synthesis of Structure # 17; 2,5-&w-(3-methoxyphenylcarbonylox>')-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 g, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added O O O 40 WO 2007/010546 565878 PCT/IN2005/000318 3-methoxybenzoyl chloride (1.45 g, 8.5 mmole) at 15 - 20 °C and stirred, allowed to attain 30 C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to pure mass (1.32 g, 69%). *H NMR (400 MHz, CDC13) 8: 0.87 (t, 3H, J = 7.0 Hz), 1.1 - 1.7 (m, 18H), 2.5 (t, 2H, J = 7.9 Hz), 3.9 (s, 6H), 6.8 (s, 1H), 7.2 - 7.7 (m, 8H). TOF MS ES: 585 (100, M+ + Na). Mp.77.1-78.6 °C. Example 18: 2,S-Di-6>-(4-methoxyphenyIcarbonyl)-3-undecyl-l,4-benzoquinone o o OMe Synthesis of Structure # 18; 2,5-fe-(4-methoxyphenylcarbonylory)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 g, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 4-methoxybenzoyl chloride (1.45 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 °C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to pure mass (1.37 g,71.7%). ]H NMR (400 MHz, CDC13) 5: 0.87 (t, 3H, J = 6.7 Hz), 1.1 - 1.7 (m, 18H), 2.5 (t, 2H, J = 7.6 Hz), 3.9 (s, 6H), 6.9 (s, 1H), 7.0 - 7.2 (m, 4H), 8.10 - 8.13 (m, 4H). TOF MS ES:. 585 (100, M1" + Na). Mp. 99.2-100.5 °C. 41 565878 WO 2007/010546 PCT/IN2005/000318 Example 19: 2,5-Di-<?-(2-iodophenylcarbonyI)-3-undecyI-l,4-benzoquinone Synthesis of Structure # 19; 2,5-Jw-(2-iodophenylcarhonyloxy)-3-undecyl-l,4-benzoquinone. To a stirred solution of 2,5-dihydroxy-3-undecyl-l,4-benzoquinone (1.0 gm, 3.4 mmole) in dichloromethane (20 mL) was added pyridine (1.1 mL, 13.6 mmole). To this, was added 2-iodo benzoylchloride (2.26 gm, 8.5 mmole) at 15-20 °C and stirred, allowed to attain 30 C and stirring was continued for 3 h (TLC). The organic layer was extracted with dichloromethane, washed (water, brine), dried (Na2S04), concentrated to crude which was purified by Si02 column chromatography (10-20% EtOAc in hexane) to a pure mass (0.89 g, 35%). NMR (300 MHz, CDC13) S: 0.87 (t, 3H, J = 6.9 Hz), 1.2 - 1.7 (m, 18H), 2.5 (t, 2H, J = 7.6 Hz), 6.8 (s, 1H), 7.2 - 8.2 (m, 8H). TOF MS ES: 777 (100, M* + Na). Mp. 64.2-67.6 Example 20: Assay for lipase inhibitory activity Preparation of test samples: Structures #1 - #19 were dissolved in lmL DMSO to obtain a 10 mM stock solution, and were vortexed to dissolution and stored at 4°C. The various concentration of working samples were prepared in 0.2 M phosphate buffer, pH-8.0. This sample was used as test sample for all further assays. C. 42 565878 WO 2007/010546 PCT/IN2005/000318 Lipase assay: Lipase assay was performed by method described by Winkler and Stuckmann, 1979, with modification. (Winkler, U.K. & Stuckmann, M. Glycogen, hyaluronate, and some other polysaccharides greatly enhance the formation of exolipase by Serratia marcescens. J. Bacteriol. 138: 663-670 (1979)) Assay was designed, using a 96-well format. The substrate used in this assay was p-nitro phenol palmitate (Sigma, Cat No- N-2752). 4.5 mg of p-nitro phenol palmitate was dissolved in 200 |il of N, N-dimethyl formamide (Sigma, Cat No, D-4551) and volume made up to 10 ml with 0.1 M pH 8.0 phosphate buffer. Pancreatic Lipase (Sigma, Cat No. L-3126) sample was prepared by dissolving the enzyme in 0.1M phosphate buffer at a concentration of 5 mg/ml. The reaction mixture consisted of 150 p.1 substrate solution; 40 jj.1 phosphate buffer (pH 8.0, 0.2 M) and 10 p.1 lipase solution. The reaction mixture was incubated at 37°C and optical density was measured at 405 nm after incubation. Enzyme activity was presented in the form of international unit (IU). Lipase activity: One enzyme unit of lipase is defined as that quantity releasing lnm of free phenol from the substrate (p-nitro phenol palmitate) per min per ml under the standard assay condition (Winkler and Stuckmann, 1979; Yadav RP, Saxena RK, Gupta R, Davidson WS., Purification and characterization of a region-specific lipase from Aspergillus terreus. Biotechnol. Appl. Biochem. (1998) 28, (243-249)). It is derived from standard graph of p-nitro phenol (Sigma, 104-8). Lipase inhibition assay: Enzyme inhibition assay was performed in a dose dependent manner .The concentration of the synthetic analogs checked were 100|oM & 200uM. The assay was similar to assay described above except 40 (il of test sample was used instead of phosphate buffer in control. Optical density was measured at 0 hr and following incubation at 37 °C. Enzyme Inhibition: Enzyme inhibition was presented in the term of relative activity and percentage inhibition simply on the basis of change in international unit (TU). 43 565878 WO 2007/010546 PCIYIN2005W00318 Table 1: Effect of compounds of structures #1 - #19 on pancreatic lipase inhibition. Sample % Inhibition % Inhibition (200jiM) (100yM) Control(no Inhibitor) 0.00 0. 00 Structure #1 69 .46 67.87 Structure #2 97.91 99.16 Structure #3 99.16 99.54 Structure #4 99.96 99. 62 Structure #5 100.00 100.00 Structure #6 100.00 100.00 Structure #7 100.00 100.00 Structure #8 100.00 100.00 Structure #9 100.00 98. 40 Structure #10 97.02 87.49 Structure #11 97.95 97.38 Structure #12 99.12 88.49 Structure #13 100.00 100.00 Structure #14 61.31 65.88 Structure #15 100.00 100.00 Structure #16 100.00 89.55 Structure #17 96. 46 78 . 31 Structure #18 94 .08 55. 64 Structure #19 100.00 29.18 Example 21: Determination oflCso Preparation of test samples: Synthetic analogues were dissolved in 1ml DMSO to obtain a 10 mM stock solution. The samples were vortexed to dissolution and stored at 4°C. The various concentration of working samples were prepared in 0.2 M phosphate buffer, pH-8.0. This sample was used as test sample for all further assays. Lipase inhibition assay: Enzyme inhibition assay was performed in a dose dependent manner .The concentration of the synthetic analogs checked were 6.25 |iM-200fi M. The assay was similar to assay described above except 40 jj.1 of test sample was used instead of phosphate buffer in control. Optical density was measured at 0 hr and following incubation at 37 °C. The enzyme activity was measured in terms of international unit (IU). 44 565878 WO 2007/010546 PCT/IN2005/000318 Lipase activity: One enzyme unit of lipase is defined as that quantity releasing lnm of free phenol from the substrate (p-nitro phenol palmitate)/min per ml under standard assay conditions. It is derived from standard graph of p-nitro phenol (Sigma, 104-8) Percent Inhibition: Enzyme inhibition was presented in the term of % inhibition simply on the basis of change in international unit (IU). IC50 calculation: IC50 of each analogue was calculated manually from dose dependent graph (6.25 |iM-200 liM) of each analogue at the concentration, where the % inhibition of lipase was measured as 50% in two near straight points (above •& below 50% inhibition). The value of IC50 was derived from linear regression. The value derived is based on interpolated data. Table 2: IC50 of compounds of Structure #1 - Structure #19 for pancreatic lipase inhibition. IC50 (PM) Structure #1 21.94 Structure #2 <6.25 Structure #3 <6.25 Structure #4 7.78 Structure #5 10.98 Structure #6 13.51 Structure #7 16.72 Structure #8 20. 61 Structure #9 22.80 Structure #10 23. 69 Structure #11 26.97 Structure #12 41.34 Structure #13 44. 68 Structure #14 45.32 Structure #15 55.57 Structure #16 72.81 Structure #17 81.91 Structure #13 94 .22 Structure #19 129.39 45 565878 WO 2007/010546 PCT/IN2005/000318 Example 22: Inhibition of Lipid absorption. Overnight fasting 4-week-old male Wistar rats (weight range: 150-200 grams) were used for the lipid absorption study. The rats were divided into two groups of 6 rats each and 100(il of blood was drawn from orbital sinus for estimation of plasma lipid profile at 0 hour. 1 ml of fat rich liquid diet was administered PO (par orally) by gavages. Additionally, experimental group was given orally 100 (ig of test compound (2,5-di-O-aroyl-3-undecyl-l,4-benzoqumone derivative Structures #1 - #19) dissolved in 500 [il of vehicle; control group received same volume of vehicle. 100 ill of blood was drawn at 1 hour post-feeding for estimation of total triglycerides. Results are shown in following table. Experimental group had significantly lower level of triglycerides. Table 3: Triglyceride levels GROUP TRIGLYCERIDES (mg/dL) HOUR <0> HOUR <1> GROUP - 1 (control) 1 77 79.5 127 135.1 2 72 160 3 54 171 4 66 63 5 79 90 6 129 200 GROUP - 2 (experimental: Structures #2 - #19) 7 64 70.6 74 66.5 8 42 48 9 66 91 10 106 67 11 76 50 12 70 69 46 </div>

Claims

<div class="application article clearfix printTableText" id="claims"> 565878 WO 2007/010546 PCT/IN2005/000318 Example 23: Inhibition of cellular uptake of Lipids Mouse macrophage cell line (J774A.1) were plated in 6-well culture plates (1 x 103 cells per well) in Dulbecco's Minimum Essential Medium (DMEM) containing 10% Fetal bovine serum. 100 |ig of oxidized low density lipoproteins (LDL) was added to each well. In each plate one of the compounds (Structure #1- #19) (10 |J.M) was added to wells in triplicate, while 3 wells were maintained as control. Experiment was terminated after 48 hours. Cells were stained with oil Red and counterstained with hematoxylin and observed under microscope. As compared to control, treatment with Structure #2 - #19 significantly inhibited uptake of LDL by macrophages. All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinaiy skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. 47 565878 RECEIVED at IPONZ on 26 March 2010 CLAIMS

1. Use of a compound selected from 2,5-dihydroxy-3-undecyl-p-benzoquinine, the compounds of any one of formulae (I), (II) and (III), optical isomers thereof, 5 polymorphs thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of said compounds, said isomers or said polymorphs, all solvates and hydrates thereof and all salts thereof,

in the manufacture of a medicament for use in a method for treatment, amelioration or prevention of a disease or condition mediated by a lipase gene family 10 enzyme comprising inhibiting or reducing activity of an enzyme belonging to lipase gene family to an extent that treats, ameliorates or prevents the disease or condition wherein R, and R2 are each independently selected from the group consisting of hydrogen, C3-C13 alkyl, C,-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 20 cycloalkyl, C4-C6 cycloalkenyl, C,-C13 alkoxyalkyl, C,-C5 alkylcycloalkyl, C,-C5

alkylcycloalkenyl, C,-C13 alkylamine, C,-Cl3 arylamine, C(0)C,-C6 alkyl, 0-C(0)C,-Cs alkyl, heterocycloalkyl, aryl, alkylaryl, C(0)aryl and 0-C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C,-C6 alkyl, cycloalkyl, 25 aryl, alkoxy, and aryloxy

O

15

(I)

O

48

565878

RECEIVED at IPONZ on 16 December 2009

groups, provided that Ri and R2 are not phenyl;

(II)

wherein R/ and R2; are each independently selected from the group consisting of C3-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-Cg cycloalkenyl, C1-C13 alkoxyalkyl, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C1-C13 alkylamine, C1-C13 aiylamine, C(0)Ci-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1 -Q alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that R/ and R21 are not phenyl;

(III)

wherein R/; and R/ are each independently selected from the group consisting of hydrogen, C1-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, Ci-Ci3 alkylamine, C1-C13 arylamine, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C(0)Ci-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl; wherein each of the foregoing groups may optionally bear 1 to 6 substituents independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups.

49

565878

RECEIVED at IPONZ on 16 December 2009

2. Use according to claim 1 wherein,

when any of Ri, R2, R/, Ri', R/'' and R2 is a said heterocycloalkyl group, the heterocycloalkyl group has up to 6 carbon atoms and includes at least one heteroatom selected from N, O and/or S; and/or when any of Ri, R2, R/, R27, Ri'' and R2// is a said aryl, alkylaryl or C(0)aryl group, or is a moiety which is substituted with a said aryl or aryloxy group, the aryl moiety is selected from phenyl, naphthyl, tetrahydronaphthyl and indenyl; and/or when any of Rj, R2, R/, R2, R/; and R2/y is a said alkylaryl moiety, the alkyl moiety is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, sec-butyl, n-pentyl and n-hexyl; and/or when any of Ri, R2, R/, R/, R/' and R2;/ is a moiety which is substituted with a said cycloalkyl group, the cycloalkyl group is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; and/or when any of Ri, R2, R/, Rj', R/' and R2" is a moiety which is substituted with a said alkoxy group, the alkoxy group is selected from methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, secondary butoxy, tertiary butoxy and 2-methoxyethoxy; and/or when either of Ri and R2 is a said 0-C(0)aryl group, the aryl moiety is selected from phenyl, naphthyl, tetrahydronaphthyl and indenyl.

3. Use according to claim 1 or 2, wherein R/ and R2''are independently selected from the group consisting of C(0)aryl, C(0)alkylaryl, C(0)haloaryl, C(0)nitroaryl, and C(0)alkoxyaryl.

4. Use according to claim 1, wherein R/ and R21* are independently selected from the group consisting of methyphenylcarbonyl, ethylphenylcarbonyl, propylphenylcarbonyl, butylphenylcarbonyl, chlorophenylcarbonyl, bromophenylcabonyl, iodophenylcarbonyl, fluorophenylcarbonyl, nitrophenylcarbonyl, methoxyphenylcarbonyl, and ethoxyphenylcarbonyl.

5.

Use according to claim 1,wherein R/ and R27 are independently selected from

50

RECEIVED at IPONZ on 16 December 2009

565878

the group consisting of 2-methyphenylcarbonyl, 3-methyphenylcarbonyl, 4-methyphenylcarbonyl, 4-ter-butylphenylcarbonyl, 2-chlorophenylcarbonyl, 3-chlorophenylcarbonyl, 4-chlorophenylcarbonyl, 2-bromophenylcarbonyl, 3-bromophenylcarbonyl, 4-bromophenylcarbonyl, 2-iodophenylcarbonyl, 3-iodophenylcarbonyl, 4-iodophenylcarbonyl, 2-fluorophenylcarbonyl, 3-fluorophenylcarbonyl, 4-fluorophenylcarbonyl, 2-nitrophenylcarbonyl, 3-nitrophenylcarbonyl, 4-nitrophenylcarbonyl, 2-methoxyphenylcarbonyl, 3-methoxyphenylcarbonyl, or 4-methoxyphenyl carbonyl.

6. Use according to claim 1, wherein the compound is selected from the group consisting of:

i) 2,5-6/sK3-fluorophenylcarbonylo.xy)-3 -undecyl-l,4-benzoquinone;

ii) 2,5-6w-(^-tertiarybutylphenylcarbonyloxy)-3 -undecyl-1,4-benzoquinone;

iii) 2,5-Z>w-(2-fluorophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone;

iv) 2,5-6w-(2-bromophenylcarbonylox>')-3-undecyl-1,4-benzoquinone;

v) 2,5-6/s-(.?-bromophenylcarbonyk).ry)-3-undecyl-l,4-benzoquinone;

vi) 2,5-6/s-(3-chlorophenylcarbonylo.ry)-3-undecyl-l,4-benzoquinone;

vii) 2,5-i;'.s-(2-chlorophenylcarbonyloxy)-3 -undecyl-1,4-benzoquinone; vii) 2,5-Z>/.s-(4-chlorophenylcarbonyl<xcy)-3-undecyl-l,4-benzoquinone;

ix) 2,5 -Mv-(4-bromophenylcarbonyloxy)-3 -undecyl-l ,4-benzoquinone;

x) 2,5-bis-{3-nitrophenylcarbonylorv)-3 -undecyl-l,4-benzoquinone;

xi) 2,5-Aw-(4-methylphenyIcarbonyloA>')-3 -undecyl-1,4-benzoquinone;

xii) 2,5-W,y-(-?-methylphenylcarbonylary)-3-undecyI-l,4-benzoquinone;

xiii) 2,5-frw-(2-nitrophenylcarbonylox^)-3-undecyl-l,4-benzoquinone;

xiv) 2,5-fe/5-(phenylcarbonylox^)-3-undecyl-l,4-benzoquinone;

xv) 2, S-fc/s-^-fluorophenylcarbonylox^-S-undecyl-l,4-benzoquinone;

xvi) 2,5 -bis-(3-methoxyphenylcarbonyloxy)-3 -undecyl-1,4-benzoquinone;

xvii) 2,5-te-(4-methoxyphenylcarbonyl0ry)-3-undecyl-l,4-benzoquinone;

xviii) 2,5-&w-(2-iodophenylcarbonyloj^)-3-undecyl-l,4-benzoquinone; optical isomers thereof, a polymorph thereof, all solvates and hydrates thereof and all

51

565878

RECEIVED at IPONZ on 26 March 2010

salts thereof.

7. Use according to any one of claims 1 to 6 wherein the medicament is for use in reducing or inhibiting metabolism, absorption, and accumulation of fat at various levels including body fluid, cell, and tissue levels in a mammal.

8. Use according to any one of claims 1 to 6 wherein the disease is selected from excess weight or obesity, hyperlipidemia, hypercholesterolemia,

hypertriglyceridemia, pancreatitis, hyperglycemia, atherosclerosis, metabolic syndromes, cardiovascular diseases, and metabolic disorders.

9. Use according to any one of claims 1 to 6 wherein the medicament is for use in a method comprising treatment or prevention of cellular or tissue damage caused by a microbial pathogen that secretes lipases.

10. Use according to any one of claims 1 to 6 wherein the medicament is for use in a method comprising treatment of a skin or hair condition.

11. Use according to claim 1 wherein the inhibiting or reducing activity of an enzyme belonging to lipase gene family is sufficient to reduce or inhibit metabolism, absorption, and accumulation of fat in body fluid, cells, and tissues.

12. Use according to any one of claims 1 to 11, wherein the medicament is for oral, topical, intranasal, intravenous, transdermal or intramucosal administration, or for administration by inhalation.

13. Use of a compound as defined in any one of claims 1 to 6 in treating a cosmetic condition.

14. A compound selected from the compounds of any one of formulae (la), (Ila) and (Ilia), and optical isomers thereof, polymorphs thereof, and pharmaceutically acceptable esters, ethers, carbamates, oximes of said compounds, said isomers or said

52

565878

RECEIVED at IPONZ on 26 March 2010

polymorphs, all solvates and hydrates thereof and all salts thereof:

O

5

(la)

O

wherein R, and R2 are each independently selected from the group consisting of (a) C,-C,3 arylamine and 0-C(0)aryl groups which carry 1 to 6 substituents, and 10 (b) C3-C13 alkyl, C,-C20 haloalkyl, C2-C13 alkenyl, C2-Cl3 alkynyl, C4-C6 cycloalkyl, C„-C6 cycloalkenyl, C,-C13 alkoxyalkyl, C,-Cs alkylcycloalkyl, C,-C5 alkylcycloalkenyl, C3-Ci3 alkylamine, C(0)C,-C6 alkyl, 0-C(0)C2-C6 alkyl, heterocycloalkyl, aryl, alkylaryl, and C(0)aryl groups which optionally carry 1 to 6 substituents, wherein said substituents are independently selected from halo, nitro, 15 amino, cyano, isocyano, thio, C2-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that R, and R2 are not phenyl;

wherein R/and R2/ are each independently selected from the group consisting of (a) a C(0)aryl group which carries 1 to 6 substituents, and (b) C3-C13 alkyl, C,-C20 haloalkyl, C2-C,3 alkenyl, C2-Cl3 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C,-25 C13 alkoxyalkyl, C,-C5 alkylcycloalkyl, C,-C5 alkylcycloalkenyl, C,-C13 alkylamine, C,-C13 arylamine, C(0)C2-C6 alkyl, heterocycloalkyl, aryl, and alkylaryl groups which optionally carry 1 to 6 substituents wherein said substituents are independently selected from halo, nitro, amino, cyano, isocyano, thio, C,-C6 alkyl, cycloalkyl, aiyl, alkoxy, and aryloxy groups, provided that R/ and R/ are not phenyl;

0

20

(Ila)

0

53

RECEIVED at IPONZ on 16 December 2009

selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, C1-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups, provided that R/ and R27 are not phenyl;

(Ilia)

wherein R/' and R2/y are each independently selected from the group consisting of (a) an aiyl group which carries 1 to 6 substituents, and (b) hydrogen, C2-C13 alkyl, C1-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 cycloalkenyl, C1-C13 alkoxyalkyl, C1-C13 alkylamine, C1-C13 arylamine, C1-C5 alkylcycloalkyl, C1-C5 alkylcycloalkenyl, C(0)Ci-C6 alkyl, heterocycloalkyl, alkylaryl, and C(0)aryl groups which optionally carry 1 to 6 substituents,

wherein substituents are independently selected from hydrogen, halo, nitro, amino, cyano, isocyano, thio, Ci-C6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups.

15. A compound of formula (Ila), as defined in claim 14, wherein R/ and R2^ independently of one another are selected from the group consisting of C(0)alkylaryl, C(0)haloaryl, C(0)nitroaryl, and C(0)alkoxyaryl.

16. A compound of formula (Ila), as defined in claim 14, wherein R/ and are as defined in claim 4 or 5.

17. The compound of claim 14, which is selected from the group consisting of:

i) 2,5-i«-(i-fluorophenylcarbonyloxj)-3-undecyl-l,4-benzoquinone;

ii)2,5-fc-(4-tertiarybutylpheny1carbonyIox>>)-3-undecyl-1,4-benzoquinone;

iii) 2,5-6w-(2-fluorophenylcarbonylojry)-3-undecyl-l,4-benzoquinone;

54

RECEIVED at IPONZ on 26 March 2010

565878

(Ilia)

wherein R/' and R/ are each independently selected from the group consisting of (a) an aryl group which carries 1 to 6 substituents, and (b) hydrogen, C2-C13 alkyl, C,-C20 haloalkyl, C2-C13 alkenyl, C2-C13 alkynyl, C4-C6 cycloalkyl, C4-C6 10 cycloalkenyl, C,-C13 alkoxyalkyl, C,-C13 alkylamine, C,-C13 arylamine, C,-C5 alkylcycloalkyl, C,-C5 alkylcycloalkenyl, C(0)C,-C6 alkyl, heterocycloalkyl,

alkylaryl, and C(0)aryl groups which optionally carry 1 to 6 substituents, wherein said substituents are independently selected from halo, nitro, amino, cyano, isocyano, thio, CrC6 alkyl, cycloalkyl, aryl, alkoxy, and aryloxy groups.

15

15. A compound of formula (Ila), as defined in claim 14, wherein R/ and R/ independently of one another are selected from the group consisting of C(0)alkylaryl, C(0)haloaryl, C(0)nitroaryl, and C(0)alkoxyaryl.

20 16. A compound of formula (Ila), as defined in claim 14, wherein R/ and R/ are as defined in claim 4 or 5.

17. The compound of claim 14, which is selected from the group consisting of: i) 2,5-6w-(3-fluorophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone; 25 ii) 2,5-&w-(4-tertiarybutylphenylcarbonyl0xy)-3-undecyl-l,4-benzoquinone;

iii) 2,5-i;5-(2-fluorophenylcarbonyloxy)-3-undecyl-lJ4-benzoquinone;

54

RECEIVED at IPONZ on 16 December 2009

iv) 2,5-6w-(2-broraophenylcarbonylojt>,)-3-imdecyl-l,4-benzoquinone;

v) 2,5-6i.s-(5-bromophenylcarbonyloxy)-3-undecyl-l,4-benzoquinone;

vi) 2, S-fos-CJ-chlorophenylcarbonylox^-S-undecyl-l,'4-benzoquinone;

vii) 2,5-6/s-(2-chlorophenylcarbonylojc>')-3-undecyl-1,4-benzoquinone;

vii) 2,5-Zj/s~(4-chlorophenylcarbonylory)-3-undecyl-l,4-benzoquinone;

ix) 2,5~6/s-(4-bromophenylcarbonylox>>)-3-undecyl-l,<4-benzoquinone;

x) 2,5-6w-(3-nitrophenylcarbonylox>')-3-undecyl-l,4-benzoquinone;

xi) 2,5-few-(4-methylphenylcarbonylorv)-3-undecyl-1,4-benzoquinone;

xii) 2,5-Z>/j'-(3-methylphenylcarbonyloxy)-3-undecyl-l,4-benzoquinone;

xiii) 2,5-Aw-(2-nitrophenylcarbonyloo:y)-3-undecyl-l,4-benzoquinone;

xiv) 2,5-6w-(4-fluorophenylcarbonylory)-3-undecyl-1,4-benzoquinone;

xv)2,5-Z»w-(3-methoxyphenylcarbonylo^)-3-undecyl-l,4-benzoquinone;

xvi)2,5-^u-(4-methoxyphenylcarbonylox>')-3-undecyl-l,4-benzoquinone;

xvii) 2,5-6w-(2-iodophenylcarbonyloxv)-3-undecyl-l,4-benzoquinone; optical isomers thereof, polymorphs thereof, all solvates and hydrates thereof and all salts thereof.

18. A pharmaceutical composition comprising a compound of any one of claims 14 to 17, and a pharmaceutically acceptable inert adjuvant, diluent or carrier.

19. A pharmaceutical composition comprising a compound of any one of claims 14 to 17, and at least one additional pharmaceutically active agent.

20. A composition for skin or hair care or cosmetic preparation comprising a compound of any one of claims 14 to 17, and an inert adjuvant, diluent or carrier.

21. A use as claimed in claim 1 substantially as herein described with reference to any example thereof.

22. A compound as claimed in claim 14 substantially as herein described with

55

565878 RECEIVED at IPONZ on 16 December 2009

reference to any example thereof.

23. A pharmaceutical composition as claimed in any one of claims 18-20 substantially as herein described with reference to any example thereof.

56

</div>